Updates are available Expression of concern dated 2024-07-23
Click to view Expression of concern: https://doi.org/10.1038/s41388-021-01697-6
-
Authors
Cingöz, Ahmet https://orcid.org/0000-0002-1111-7752
Ozyerli-Goknar, Ezgi
Morova, Tunc
Seker-Polat, Fidan
Esai Selvan, Myvizhi https://orcid.org/0000-0003-4640-5727
Gümüş, Zeynep Hülya https://orcid.org/0000-0002-7364-2202
Bhere, Deepak https://orcid.org/0000-0003-4142-5518
Shah, Khalid https://orcid.org/0000-0002-5474-0974
Solaroglu, Ihsan
Bagci-Onder, Tugba https://orcid.org/0000-0003-3646-2613
- License Information
-
More Information
Article History
Received: 13 May 2019
Revised: 21 January 2021
Accepted: 4 February 2021
First Online: 25 March 2021
Change Date: 4 March 2024
Change Type: Update
Change Details: Editor's note: Readers are alerted that concerns have been raised regarding the reliability of data presented in this article. Further editorial action will be taken if appropriate once the investigation into the concerns is complete and all parties have been given an opportunity to respond in full.
Change Date: 23 July 2024
Change Type: ExpressionOfConcern
Change Details: An Editorial Expression of Concern to this paper has been published:
Change Details: https://doi.org/10.1038/s41388-024-03110-4
Compliance with ethical standards
:
: KS owns equity in and is a member of the Board of Directors of AMASA Therapeutics, a company developing stem cell-based therapies for cancer. KS’s interests were reviewed and are managed by Brigham and Women’s Hospital and Partners HealthCare in accordance with their conflict of interest policies.
